Radiation therapy for primary central nervous system lymphoma

Area of Science:

• Neuro-oncology
• Radiation Oncology
• Hematology

Background:

• Historically, radiation therapy was a cornerstone for primary central nervous system lymphoma (PCNSL) treatment.
• The advent of systemic chemotherapy has altered the therapeutic landscape for PCNSL.
• Evolving treatment strategies necessitate a re-evaluation of radiotherapy's role in PCNSL management.

Purpose of the Study:

• To discuss the current role and optimal application of radiotherapy in primary central nervous system lymphoma (PCNSL) treatment.
• To analyze treatment volumes and radiation doses for PCNSL patients.
• To assess the impact of radiotherapy on PCNSL patient prognosis.

Main Methods:

• Analysis of nationwide Japanese survey data on PCNSL patients.
• Review of treatment strategies involving radiation therapy and chemotherapy.
• Evaluation of prognostic trends in PCNSL patients over time.

Main Results:

• Patient prognosis for PCNSL improved significantly during the 1990s.
• This improvement is partly attributed to the integration of high-dose methotrexate-based chemotherapy.
• Patients receiving radiation therapy alone also demonstrated enhanced survival rates.

Conclusions:

• Radiotherapy continues to be a vital component in the curative strategy for primary central nervous system lymphoma (PCNSL).
• Optimizing radiotherapy techniques, including treatment volume and dose, is essential.
• The combination of modern chemotherapy and radiotherapy offers the best outlook for PCNSL patients.